3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Melanoma
10
Uveal Melanoma
3
Multiple Myeloma
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Eye Neoplasms
1
Interventions
Vincristine
25
Cyclophosphamide
25
Irinotecan
21
Temozolomide
18
Doxorubicin
16
Radiotherapy
15
Filgrastim
15
Ifosfamide
14
Dactinomycin
14
Etoposide
11
Vinorelbine
9
Melphalan
9
Magnetic Resonance Spectroscopy
9
Granulocyte Colony-Stimulating Factor
9
Radiation
8
pegfilgrastim
7
X-Rays
7
Specimen Handling
7
Sirolimus
7
Topotecan
6
Phantoms, Imaging
6
Peripheral Blood Stem Cell Transplantation
6
Gemcitabine
6
cixutumumab
5
Busulfan
5
Biopsy
5
temsirolimus
4
irinotecan sucrosofate
4
fludarabine
4
etoposide phosphate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Rhabdomyosarcoma
×
MAGEA3 protein, human
×
Clear all
NCT00944580
2017-11-24
A Vaccine Study for High Risk Cancers
Penn State University
Phase 1
Withdrawn